Header Image for Mobic vs Ultram

Mobic vs Ultram

Listen to the article instead of reading through it.
0:00

Overview

Mobic Information

Ultram Information

Comparative Analysis

Mobic Prescription Information

Ultram Prescription Information

Mobic Side Effects

Ultram Side Effects

Safety Information

Cost Information

Market Information

Summary

Introduction

For patients dealing with chronic pain or inflammatory conditions such as arthritis, certain drugs that alter the body's production of substances that cause inflammation and pain can help in managing symptoms. Mobic (Meloxicam) and Ultram (Tramadol) are two such medications often prescribed for these purposes. Each impacts different processes in the body but both aim to provide relief from discomfort. Mobic is a non-steroidal anti-inflammatory drug (NSAID), working by reducing hormones that cause inflammation and pain in the body. On the other hand, Ultram is classified as an opioid analgesic, primarily affecting how your brain perceives sensation of pain.

Mobic vs Ultram Side By Side

AttributeMobicUltram
Brand NameMobicUltram
ContraindicationsShould not be taken with MAO inhibitors or if there are severe allergic reactions to NSAIDs.Should not be used with MAO inhibitors or in patients with a history of seizures or addiction.
Cost$10 to $20 for 30 capsules (15mg each)$9 to $35 for 60 pills
Generic NameMeloxicamTramadol
Most Serious Side EffectStomach ulcers, severe allergic reactions, unexpected weight gain, swelling of the legs, ankles, and feet.Serotonin syndrome, seizures, addiction, respiratory depression.
Severe Drug InteractionsCan interact dangerously with other NSAIDs, blood thinners, and MAO inhibitors.Can interact dangerously with MAO inhibitors, SSRIs, SNRIs, and other opioids.
Typical Dose7.5-15 mg/day25 mg/day initially, up to 400 mg/day

What is Mobic?

Meloxicam (the generic name for Mobic) is a nonsteroidal anti-inflammatory drug (NSAID) that was first approved by the FDA in 2000. Mobic works by reducing hormones that cause inflammation and pain in the body, primarily prescribed to relieve symptoms of osteoarthritis or rheumatoid arthritis. Unlike Prozac, it does not affect neurotransmitter levels but instead inhibits an enzyme known as COX-2 which plays a crucial role in triggering pain and inflammation.

On the other hand, Tramadol (the generic name for Ultram) belongs to a different class of drugs called opioid analgesics. It was first approved by the FDA in 1995 and acts on mu-opioid receptors in the brain to block pain signals while also increasing serotonin release - offering dual action against both moderate and severe pain. While Ultram can be more effective at relieving intense acute or chronic pain than Mobic, it has potential side effects including addiction due to its opioid component.

What conditions is Mobic approved to treat?

Mobic is approved for the treatment of various types of pain and inflammation:

  • Osteoarthritis, a common form of arthritis that causes breaking down of joint cartilage
  • Rheumatoid arthritis, an autoimmune disease in which the body's immune system mistakenly attacks its own tissues causing inflammation in the joints
  • Juvenile rheumatoid arthritis, similar to rheumatoid arthritis but occurs in children.

Ultram (tramadol) on the other hand is used primarily for managing moderate to moderately severe acute or chronic pain. It's effective whether or not the pain is linked with cancer or a nerve disorder.

How does Mobic help with these illnesses?

Mobic, also known as meloxicam, helps to manage pain and inflammation by inhibiting the production of prostaglandins in the body. It does this by blocking cyclooxygenase-2 (COX-2), an enzyme that is involved in producing these substances which promote inflammation, swelling, fever and pain. Prostaglandins are produced within the body's cells by the enzymatic conversion of arachidonic acid.

On the other hand, Ultram (tramadol) works differently. As a centrally acting opioid analgesic, it changes how your brain perceives pain rather than targeting the root cause of inflammation like Mobic does. Tramadol acts on mu-opioid receptors and also increases concentrations of serotonin and norepinephrine in your system by preventing their reuptake into nerve endings.

Therefore, while both drugs can be used for managing moderate to severe pain conditions effectively - Mobic primarily targets inflammation as a root cause while Ultram focuses on altering perception of pain sensation at central nervous system level.

What is Ultram?

Ultram, also known by its generic name tramadol, is a synthetic opioid analgesic that acts as an agonist at mu-opioid receptors in the brain. This means it binds to these receptors and activates them, leading to pain relief. It was first approved by the FDA in 1995. Unlike Mobic (meloxicam), Ultram has dual action: it not only works on the opioid receptors for pain relief but also inhibits reuptake of norepinephrine and serotonin neurotransmitters, which can additionally help with pain management.

This unique mechanism of action distinguishes it from non-steroidal anti-inflammatory drugs (NSAIDs) like Mobic. Its side-effect profile is different too; while NSAIDs may cause gastrointestinal issues such as stomach upset or ulcers, Ultram's side effects are more akin to those associated with opioids - including nausea, constipation and potential risk of dependency if improperly used. However, when used appropriately under medical supervision Ultram can provide effective relief for moderate to severe acute or chronic pain conditions that might not respond adequately to typical NSAIDs such as Mobic.

What conditions is Ultram approved to treat?

Ultram, also known as tramadol, is a strong painkiller that's used to treat moderate to severe pain. It's approved by the FDA for the following conditions:

  • Postoperative pain management
  • Chronic conditions such as fibromyalgia or osteoarthritis
  • Acute musculoskeletal pains Remember, Ultram should be used under doctor’s supervision due to its potential for dependency and addiction.

How does Ultram help with these illnesses?

Ultram, also known as tramadol, is a centrally acting analgesic that primarily works by binding to the brain's μ-opioid receptors. This action helps to manage moderate to severe pain effectively. Ultram has an advantage over other medications like Mobic (Meloxicam) because it also inhibits the reuptake of norepinephrine and serotonin in your brain. Increased levels of these neurotransmitters can change the way your body senses pain, thereby providing relief from discomfort. Furthermore, Ultram can be used for both acute and chronic forms of pain since it does not significantly affect prostaglandins, meaning there are fewer gastrointestinal side effects compared with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Therefore, when patients don't respond well or have contraindications for NSAID use such as Mobic, Ultram might be a suitable alternative or could possibly be combined with NSAIDs under medical supervision.

How effective are both Mobic and Ultram?

Both meloxicam (Mobic) and tramadol (Ultram) have established histories of success in treating moderate to severe pain, with both being initially approved by the FDA in the mid-1990s. However, they are different types of drugs; meloxicam is a nonsteroidal anti-inflammatory drug (NSAID), while tramadol is an opioid analgesic. Because they act on different aspects of pain sensation, they may be prescribed under different circumstances.

The effectiveness of meloxicam and tramadol has been directly compared in several studies. For instance, a 2007 study found that both drugs were similarly effective at reducing pain after knee surgery. Both also had similar safety profiles in this study. Another clinical trial conducted in 2011 found that patients treated with either drug showed significant improvements in their ability to perform daily activities without experiencing debilitating pain.

A 2013 review highlighted that meloxicam can effectively reduce inflammation and alleviate symptoms from the first day of treatment onwards due to its long half-life allowing for once-daily dosing. This review also emphasized its favorable safety profile compared to other NSAIDs like diclofenac or ibuprofen because it has less gastrointestinal side effects such as ulcers or bleeding incidents which can be serious issues for some patients especially those who are elderly.

Meanwhile, a meta-analysis published in 2016 revealed that tramadol is more effective than placebo at treating acute postoperative pain and chronic forms of severe osteoarthritis-related joint pains where stronger analgesia would often be required over NSAIDs alone due to their inadequate relief offered against such intense levels of discomfort experienced by these individuals suffering from these particular conditions. Tramadol's unique dual mechanism action involving mu-opioid receptor agonism combined with serotonin-norepinephrine reuptake inhibition allows it not only reduce physical sensations associated but also potentially help improve mood disturbances commonly linked alongside chronic painful disorders thus providing broader spectrum coverage during management strategies employed here when dealing therapeutically within these settings respectively.

abstract image of a researcher studying a bottle of drug.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Mobic typically prescribed?

Oral dosages of Mobic (Meloxicam) typically range from 7.5-15 mg/day, but research suggests that a dose of 7.5 mg/day is adequate for managing osteoarthritis and rheumatoid arthritis in most people. For Ultram (Tramadol), the initial oral dosage usually starts at 50-100 mg every four to six hours, with a maximum daily limit of 400mg. However, due to its potential for dependence and abuse, the lowest effective dose should be used for the shortest duration possible.

At what dose is Ultram typically prescribed?

Ultram treatment is generally initiated at a dosage of 25 mg/day, taken orally in the morning. The dose can then be gradually escalated by 25 to 50 mg every three days up to 100-200mg per day divided into two doses, spaced around six hours apart. If necessary, the maximum daily dose can be increased to 400 mg/day divided into four doses of 100 mg and spaced approximately five hours apart. This adjustment should only occur if there's insufficient response or tolerance developed over time with the current dosage after several weeks.

What are the most common side effects for Mobic?

Common side effects of Mobic (Meloxicam) may include:

  • Indigestion, nausea, vomiting, and stomach pain
  • Diarrhea or constipation
  • Dizziness or headache
  • Swelling in your hands or feet

On the other hand, Ultram (Tramadol) has potential side effects that include:

  • Constipation
  • Nausea and vomiting
  • Headache
  • Dizziness and lightheadedness
  • Drowsiness/sleepiness
  • Weakness or lack of energy

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Mobic?

Mobic (Meloxicam) and Ultram (Tramadol) are both pain relievers, but they work differently and can have different side effects. For Mobic:

  • Severe allergic reactions such as difficulty breathing or swallowing, chest tightness, swelling in your face or hands, a rash or hives that itch
  • Unexpected weight gain
  • Swelling of the legs, ankles and feet due to fluid retention
  • Stomach ulcers which may cause heartburn; indigestion; bloody vomit; blood in stools or black stools.

For Ultram:

  • A rare but serious condition called serotonin syndrome: symptoms include fast heartbeat, hallucinations (seeing things), fever, loss of coordination
  • Changes in behavior including feelings of self-harm or suicide
  • Difficulty breathing or shallow breathing
  • Seizures: this is more likely if you've had seizures before or if you're taking other medications that can also lead to seizures.

It's vital to discuss all potential side effects with your healthcare provider before starting any new medication. Your doctor will be able to guide you on the best course of action based on your specific circumstances.

What are the most common side effects for Ultram?

Ultram, also known as tramadol, can present with side effects such as:

  • Nausea, vomiting, loss of appetite
  • Constipation
  • Dizziness or headache
  • Sleep problems (insomnia)
  • Sweating and flushing of the skin
  • Dry mouth or sore throat
  • Feeling unusually tired or lethargic
    Although not common, Ultram can occasionally cause serious side effects like fast heartbeat, feelings of nervousness and confusion. It's important to report any unusual symptoms to your healthcare provider right away.

Are there any potential serious side effects for Ultram?

While Ultram is generally well-tolerated, it can have serious side effects in some cases. These may include:

  • Allergic reactions: Symptoms might involve hives, itching, difficulty breathing or swallowing due to throat swelling, and skin rash with blistering and peeling.
  • Mental health issues: It's important to watch out for new or worsening feelings of depression or anxiety, as well as thoughts about self-harm.
  • Neurological problems: In rare circumstances Ultram can cause seizures even in people without a history of epilepsy.
  • Vision changes: If you notice blurred vision or other unusual eye-related symptoms like seeing halos around lights while taking this medication; seek immediate medical attention.
  • Heart rhythm abnormalities: Fast or irregular heartbeats could be indicative of a problem that needs to be addressed by your healthcare provider. These side effects are not common but if they occur, stop using the drug immediately and consult your doctor.

Contraindications for Mobic and Ultram?

Both Mobic (meloxicam) and Ultram (tramadol), like many pain relief medications, can cause serious side effects. If you notice any severe reactions such as breathing difficulties, chest pain or rapid heartbeat, swelling of the hands or feet, unusual fatigue or weight loss/gain - seek immediate medical help.

Neither Mobic nor Ultram should be taken if you are using certain other drugs like MAO inhibitors (MAOIs). Always make sure to inform your doctor about all the medications that you are taking; this includes prescription and over-the-counter medicines, vitamins, and herbal products. If you have been taking an MAOI, it will need a period of at least 14 days to flush out from your system before starting with either meloxicam or tramadol in order to prevent potentially dangerous interactions.

How much do Mobic and Ultram cost?

For the brand name versions of these drugs:

  • The price of 30 tablets of Mobic (15 mg) averages around $260, which works out to roughly $8.67 per day.
  • In contrast, Ultram (50 mg), or tramadol its generic name, costs approximately $80 for a package containing 60 tablets; that's about $2.66 per day.

Thus, if you are in need of pain management and your doctor sees no significant difference between these two medications for your condition, then Ultram is less expensive on a per-day treatment basis. However, cost should not be the primary consideration when determining which medication is right for you.

As with most drugs, their generic counterparts offer a more affordable option:

  • Meloxicam - the generic version of Mobic - can be found at an average price range from $10 to $20 for a pack of 30 capsules (15mg each). This translates to about $.33 to $.67 daily.
  • Tramadol - generic Ultram – usually costs between $9 and $35 dollars for 60 pills. At typical dosages this calculates as low as $.15 up to about $.58 per day.

Remember that prices may vary depending on factors such as location and insurance coverage.

Popularity of Mobic and Ultram

Meloxicam, also known by the brand name Mobic, is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for pain relief from arthritis. In 2020, it was estimated that about 20 million prescriptions were filled in the US for meloxicam. This accounted for just under 30% of NSAID prescriptions in the US and has had steady usage over the past decade.

On the other hand, tramadol, often sold under brand names such as Ultram, is an opioid pain medication used to treat moderate to severe pain. In contrast to meloxicam's more specific use cases like arthritis-related pain relief, tramadol has a broader range of applications due to its powerful analgesic properties. Tramadol was prescribed approximately 12 million times across America in 2020, accounting for around 3% of all prescription analgesics given out that year. The prevalence of tramadol has been steadily increasing since entering wider medical use towards the end of last century.

Conclusion

Both Mobic (meloxicam) and Ultram (tramadol) are frequently prescribed to manage moderate to severe pain, with a long-standing record of usage and numerous clinical studies highlighting their efficacy compared to placebo treatments. In some cases, the drugs may be used concurrently for enhanced analgesia, but careful consideration by a physician is essential due to potential drug-drug interactions.

Their mechanisms of action differ significantly; Mobic primarily inhibits COX-2 enzymes reducing inflammation and pain in conditions such as osteoarthritis or rheumatoid arthritis, while Ultram acts on opioid receptors and inhibits serotonin/norepinephrine reuptake providing relief from acute or chronic pain. The choice between these two medications generally depends on the type of pain being treated.

Both drugs come in generic forms which constitute significant cost savings especially for patients paying out-of-pocket. On starting either medication an adjustment period may be required before noticeable effects take place.

While they share similar side effect profiles - including dizziness, nausea, constipation - Ultram has additional considerations due its opioid nature leading to potential dependency issues if not properly managed. Patients must closely monitor any changes in their condition when beginning treatment with either drug and should seek medical help immediately if they notice any worsening symptoms or adverse reactions.

Refrences

  • Yocum, D. (2000, October 23). Safety and Efficacy of Meloxicam in the Treatment of Osteoarthritis. Archives of Internal Medicine. American Medical Association (AMA).http://doi.org/10.1001/archinte.160.19.2947
  • OGINO, K., SAITO, K., OSUGI, T., & SATOH, H. (2002). Meloxicam (Mobic): a review of its pharmacological and clinical profile. Folia Pharmacologica Japonica. Japanese Pharmacological Society.http://doi.org/10.1254/fpj.120.391
  • Fleischmann, R., Iqbal, I., & Slobodin, G. (2002, October). Meloxicam. Expert Opinion on Pharmacotherapy. Informa Healthcare.http://doi.org/10.1517/14656566.3.10.1501
  • Minami, K., Ogata, J., & Uezono, Y. (2015, August 21). What is the main mechanism of tramadol?. Naunyn-Schmiedeberg's Archives of Pharmacology. Springer Science and Business Media LLC.http://doi.org/10.1007/s00210-015-1167-5
  • Aronson, M. D. (1997, May). Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: constrating therapies for the treatment of chronic pain. Clinical Therapeutics. Elsevier BV.http://doi.org/10.1016/s0149-2918(97)80127-0